Investigating the effect of budesonide nebulizer on healing and treatment process of children with pneumonia aged 1month to 5 years: a randomized clinical trial

Investigating the effect of budesonide nebulizer on healing and treatment process of children with pneumonia aged 1 month to 5 years: a randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240204060891N1

Enrollment

110

Registered

2024-02-15

Start date

2024-03-05

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

community acquired pneumonia.

Interventions

Intervention 1: Intervention group: budesonide recipient group. Intervention 2: Control group: The group not receiving budesonide.

Eligibility

Sex/Gender

All

Age

1 Months to 5 Years

Inclusion criteria

Inclusion criteria: age between 1 month to 5 years community acquired pneumonia diagnosed by pediatrician Informed consent of the child's family to enter the study Observing and recording complete symptoms of patient during treatment

Exclusion criteria

Exclusion criteria: Metabolic disorder cardiovascular disorder hyper reactive airway disease coagulopathy psychological disorder diabetes Immunocompromised patients Discontinuation of standard treatment for any possible reason Reluctance to continue treatment

Design outcomes

Primary

Measure	Time frame
Average score of PRESS. Timepoint: Measuring the PRESS score before the study, on days 1, 2, 3, 4, and 5 and after the end of the trial. Method of measurement: Pediatric Respiratory Severity Score (PRESS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Banitalebi

Shahre-kord University of Medical Sciences

st-banitalebi@skums.ac.ir+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026